Fairvalue-Calculator Fairvalue-Calculator
EN DE

Chi Sheng Pharma & Biotech Co (4111) Fair Value & Analysis

Healthcare · TW · Market cap 1.8B TWD

Price30.00 TWD
Fair Value59.40 TWD
Upside+98.0%
Quality95/100
Evidence: High Range 42.97 TWD – 73.56 TWD

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Chi Sheng Pharma & Biotech Co (4111) currently trades at 30.00 TWD, while our model-based Fair Value estimate is 59.40 TWD — implying the stock looks roughly 98.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. Its product portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic agents; hormones and adrenal cortical steroids; autonomic nerve agents; antihistamines and antipruritics; antipyretics and analgesics; antitussives and anti-asthmatics; gastro-intestinal preparations; local anesthetic preparations; hemodialysis concentrate and external solutions; peritoneal dialysis solutions; and others. The company also offers medical devices, fat emulsion products, anesthetic products, hemostatic solutions, food and health food products, functional drinks, skin care products and cosmetics, and veterinary medicinal products. In addition, it provides externally applied medi…

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -62% EssilorLuxottica Société anonyme (ESLOF) -44% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -15% Becton, Dickinson and Company (BDX) -22% Alcon Inc (ALC) -44%

Frequently asked questions

Is Chi Sheng Pharma & Biotech Co (4111) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 59.40 TWD versus a price of 30.00 TWD — about +98% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 4111?
Our 21-model fair value for Chi Sheng Pharma & Biotech Co is 59.40 TWD (as of Jun 25, 2026), built from audited fundamentals. The current price is 30.00 TWD.
What is the quality score of 4111?
Chi Sheng Pharma & Biotech Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.